公开(公告)号：US20230340423A1

公开(公告)日：2023-10-26

申请号：US18010740

申请日：2021-07-07

申请人： CODAGENIX INC.

发明人： John Robert Coleman ,  Steffen Mueller ,  Chen Yang ,  Ying Wang ,  Yutong Song

IPC分类号： C12N7/00 ,  C12Q1/70 ,  C12Q1/686

CPC分类号： C12N7/00 ,  C12Q1/70 ,  C12Q1/686 ,  C12N2770/20021 ,  C12N2770/24121

摘要： The present invention describes methods of generating a modified viral genome, producing infectious RNA, and generating modified viruses. The modified viral genome, infections RNA, and modified viruses comprise deoptimized nucleic acids; for example, codon-pair deoptimized or synonymous codon deoptimized. These modified viruses can be used in vaccines and methods of eliciting a protective immune response.

公开(公告)号：US20240299533A1

公开(公告)日：2024-09-12

申请号：US18574973

申请日：2022-06-30

申请人： Codagenix Inc. ,  Serum Institute of India Private Limited

发明人： Steffen Mueller ,  John Robert Coleman ,  Ying Wang ,  Chen Yang ,  Yutong Song

IPC分类号： A61K39/215 ,  A61K9/00 ,  A61K39/00 ,  A61P31/14 ,  C07K14/005 ,  C12N7/00

CPC分类号： A61K39/215 ,  A61K9/0043 ,  A61P31/14 ,  C07K14/005 ,  C12N7/00 ,  A61K2039/5254 ,  A61K2039/543 ,  A61K2039/545 ,  C12N2770/20021 ,  C12N2770/20022 ,  C12N2770/20034

摘要： Described herein are modified SARS-CoV-2 variants. These viruses have been recoded, for example, codon deoptimized or codon pair bias deoptimized and are useful for reducing the likelihood or severity of a SARS-CoV-2 variant infection, preventing a SARS-CoV-2 variant infection, eliciting and immune response, or treating a SARS-CoV-2 variant infection.

公开(公告)号：US20240165217A1

公开(公告)日：2024-05-23

申请号：US18283130

申请日：2022-04-08

申请人： CODAGENIX INC.

发明人： Steffen Mueller ,  John Robert Coleman ,  Sybil Tasker ,  Anna Kushnir

IPC分类号： A61K39/12 ,  A61K39/00 ,  A61P37/02

CPC分类号： A61K39/12 ,  A61P37/02 ,  A61K2039/5254 ,  A61K2039/543 ,  A61K2039/545 ,  A61K2039/575 ,  C12N2760/18534 ,  C12N2760/18562 ,  C12N2760/18571

摘要： The present invention provides for methods of vaccination and eliciting a IgA immune response and cellular immune response, including T-cell immune response by administering a deoptimized respiratory syncytial virus (RSV).

公开(公告)号：US20230117167A1

公开(公告)日：2023-04-20

申请号：US17794862

申请日：2021-01-27

申请人： CODAGENIX INC. ,  SERUM INSTITUTE OF INDIA PRIVATE LIMITED

发明人： Steffen Mueller ,  John Robert Coleman ,  Ying Wang ,  Chen Yang

IPC分类号： C07K14/005 ,  A61K39/215 ,  A61P31/14

摘要： Described herein are modified SARS-CoV-2 coronaviruses. These viruses have been recoded, for example, codon deoptimized or codon pair bias deoptimized and are useful for reducing the likelihood or severity of a SARS-CoV-2 coronavirus infection, preventing a SARS-CoV-2 coronavirus infection, eliciting and immune response, or treating a SARS-CoV-2 coronavirus infection.

公开(公告)号：US12054519B2

公开(公告)日：2024-08-06

申请号：US17851905

申请日：2022-06-28

申请人： THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES ,  CODAGENIX, INC.

发明人： Cyril Le Nouen ,  Ursula J. Buchholz ,  Peter L. Collins ,  Steffen Mueller

IPC分类号： A61K39/155 ,  A61K9/00 ,  A61K39/00 ,  A61K39/12 ,  A61P31/20 ,  C07K14/08 ,  C12N7/00 ,  C12N7/04

CPC分类号： C07K14/08 ,  A61K9/0019 ,  A61K9/0043 ,  A61K39/155 ,  A61P31/20 ,  C12N7/04 ,  C12N2760/00021 ,  C12N2760/00034 ,  C12N2760/00062

摘要： Reported herein are presumptively de-attenuating mutations that are useful, either individually or in combinations that may include other known mutations, in producing recombinant strains of human respiratory syncytial virus (RSV) exhibiting attenuation phenotypes. Also described herein is a novel RSV construct, Min_L-NPM2-1(N88K)L, which exhibits an attenuated phenotype, is stable and is as immunogenic as wild type RSV. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Exemplary vaccine candidates are described. Also provided are polynucleotide sequences capable of encoding the described viruses, as well as methods for producing and using the viruses.

公开(公告)号：US20220347285A1

公开(公告)日：2022-11-03

申请号：US17621125

申请日：2020-06-23

申请人： CODAGENIX INC.

发明人： Steffen Mueller ,  John Robert Coleman ,  Charles Stauft ,  Ying Wang

IPC分类号： A61K39/12 ,  C12N7/00 ,  A61P31/14

摘要： The present invention provides for modified Flavivirus such as a modified dengue virus type 1, 2, 3, 4, a combination of these, or a tetravalent combination of these. The modification according to various aspects of the invention results in reduced viral protein expression compared to a parent virus, wherein the reduction in expression is the result of recoding one or more regions of the virus. For example, the prM, or envelope (E) region can be recoded. In various embodiments one or more regions are recoded by reducing the codon pair bias or codon usage bias of the protein-encoding sequence. These modified Flaviviruses are used as vaccine compositions to provide a protective immune response.

公开(公告)号：US20210228705A1

公开(公告)日：2021-07-29

申请号：US16769102

申请日：2018-12-21

申请人： CODAGENIX INC.

发明人： John Robert Coleman ,  Steffen Mueller ,  Chen Yang ,  Ying Wang ,  Charles Stauft

IPC分类号： A61K39/13 ,  A61K39/145 ,  C12N7/00

摘要： The present invention is the use of designed recombinant viruses for the treatment of various forms of malignant tumors. The recombinant viruses of the invention are those in which one or more regions of the wild type virus was exchanged with a synthetic recoded sequence that reduces the codon pair score relative to human codon pair bias, or that increase the number for CpG di-nucleotides, or that increases the number of UpA di-nucleotides. The method of the present invention is particularly useful for the treatment of malignant tumors in various organs, such as: breast, skin, colon, bronchial passage, epithelial lining of the gastrointestinal, upper respiratory and genito-urinary tracts, liver, prostate and the brain. Astounding remissions in experimental animals have been demonstrated for the treatment of malignant glioblastoma multiforme, as well as for the treatment of breast cancer and melanoma as well.

公开(公告)号：US20240293527A1

公开(公告)日：2024-09-05

申请号：US18572482

申请日：2022-07-07

申请人： Codagenix Inc.

发明人： John Robert Coleman ,  Steffen Mueller ,  Ying Wang ,  Chen Yang

IPC分类号： A61K39/12 ,  A61K39/00 ,  A61P37/04 ,  C07K14/005

CPC分类号： A61K39/12 ,  A61P37/04 ,  C07K14/005 ,  A61K2039/5254 ,  A61K2039/545 ,  A61K2039/585 ,  C12N2770/24122 ,  C12N2770/24134 ,  C12N2770/24162 ,  C12N2770/24171

摘要： The present invention relates to deoptimized Yellow Fever viruses and their uses for the treatment of various forms of malignant tumors, and as vaccines against Yellow Fever. The method of the present invention is particularly useful for the treatment of malignant tumors in various organs, such as: breast, skin, colon, bronchial passage, epithelial lining of the gastrointestinal, upper respiratory and genito-urinary tracts, liver, prostate and the brain.

公开(公告)号：US11793870B2

公开(公告)日：2023-10-24

申请号：US17330545

申请日：2021-05-26

申请人： The United States of America, as represented by the Secretary of Agriculture ,  CODAGENIX INC.

发明人： Teresa B. De Los Santos ,  Aida E. Rieder ,  Fayna C. Diaz-San Segundo ,  Anna Kloc ,  John R. Coleman ,  Steffen Mueller ,  Gisselle N. Medina

IPC分类号： A61K39/135 ,  C12N7/00 ,  A61K39/00

CPC分类号： A61K39/135 ,  C12N7/00 ,  A61K2039/5254 ,  A61K2039/552 ,  C12N2770/32121 ,  C12N2770/32134

摘要： The present disclosure describes deoptimized foot and mouth viruses and their use for prophylactic and therapeutic treatment of mammalian subjects. The recombinant viruses provided herein include alterations in several genomic regions as well as Differentiating Infected from Vaccinated Animals (DIVA) markers.

公开(公告)号：US20220241359A1

公开(公告)日：2022-08-04

申请号：US17610026

申请日：2020-05-14

申请人： CODAGENIX INC.

发明人： John Robert Coleman ,  Steffen Mueller ,  Charles Stauft ,  Ying Wang

IPC分类号： A61K35/768 ,  A61K45/06 ,  A61K39/12 ,  C12N7/00

摘要： The present invention is the use of designed recombinant viruses for the treatment of various forms of malignant tumors using attenuated Yellow Fever virus. The method of the present invention is particularly useful for the treatment of malignant tumors in various organs, such as: breast, skin, colon, bronchial passage, epithelial lining of the gastrointestinal, upper respiratory and genito-urinary tracts, liver, prostate and the brain. Astounding remissions in experimental animals have been demonstrated for the treatment of treatment of breast cancer and melanoma.